Summary Dendritic cells (DCs) loaded with tumour antigens have been successfully used to induce protective tumour immunity in murine models and human trials. However, it is still unclear which DC administration route elicits a superior therapeutic effect. Herein, we investigated the vaccine efficiency of DC2.4 cells, a murine dendritic cell line, pulsed with ovalbumin (OVA) in the murine E.G7-OVA tumour model after immunization via various routes. After a single vaccination using 1 × 10 6 OVA-pulsed DC2.4 cells, tumour was completely rejected in the intradermally (i.d.; three of four mice), subcutaneously (s.c.; three of four mice), and intraperitoneally (i.p.; one of four mice) immunized groups. Double vaccinations enhanced the anti-tumour effect in all groups except the intravenous (i.v.) group, which failed to achieve complete rejection. The anti-tumour efficacy of each immunization route was correlated with the OVA-specific cytotoxic T lymphocyte (CTL) activity evaluated on day 7 post-vaccination. Furthermore, the accumulation of DC2.4 cells in the regional lymph nodes was detected only in the i.d.-and s.c.-injected groups. These results demonstrate that the administration route of antigen-loaded DCs affects the migration of DCs to lymphoid tissues and the magnitude of antigen-specific CTL response. Furthermore, the immunization route affects vaccine efficiency.
CD8
+ cytotoxic T lymphocytes (CTLs) kill neoplastic cells through the recognition of short peptide epitopes (8-12 amino acids long) presented by major histocompatibility complex (MHC) class I molecules that are expressed on the target cell surface (Kronenberg et al, 1986; Henkart, 1994) . Although the recognition of peptide-MHC class I complexes is sufficient to trigger tumour cell lysis, priming of CTL responses requires the presentation of the relevant antigen by professional antigen-presenting cells (APCs) capable of providing co-stimulation. Vaccines and immunotherapies that preferentially prime this component of the immune response are critical for establishing effective host tumour immunity.
Dendritic cells (DCs) are professional APCs playing a key function in the immune system as initiators of T-cell responses against microbial pathogens and tumours (Steinman, 1991; Banchereau and Steinman, 1998) . Immature DCs capture and process antigens in peripheral tissues and begin to mature. The mature DCs migrate to lymphoid organs, where they stimulate naïve T cells through the signals of both MHC molecules presenting antigen-peptides and costimulatory molecules (Austyn et al, 1988; Rock, 1996) . Therefore, immunization using DCs loaded with tumour-associated antigens (TAAs) is potentially a powerful method of inducing anti-tumour immunity. In fact, a number of studies have shown that immunization of mice by DCs pulsed with TAAs can prime a tumour-specific CTL response and engender protective tumour immunity (Mayordomo et al, 1995; Celluzzi et al, 1996; Nair et al, 1997) . These results provide a promising experimental basis for developing clinical trials of the anti-tumour therapy using DCs (Hsu et al, 1996; Nestle et al, 1998; Lodge et al, 2000) . However, further investigation of DC-based immunotherapy is required to: (1) establish efficient methods for collection and expansion of large numbers of DC precursors (Romani et al, 1994; Bernhard et al, 1995) ; (2) improve methods for induction and purification of effective DCs (Fearnley et al, 1997; Brossart et al, 1998; Lutz et al, 1999; Muller et al, 2000) ; (3) identify and select antigens (e.g. peptides, proteins, DNA, mRNA, or tumour lysate) that can elicit specific and effective immune responses (Ashley et al, 1997; Nestle et al, 1998; Philip et al, 2000) ; (4) develop methods for efficient introduction of antigens into DCs (Nair et al, 1992; Arthur et al, 1997; Gong et al, 1997; Tillman et al, 1999) ; (5) identify an optimized DC-immunization protocol (Eggert et al, 1999; Fallarino et al, 1999; Lappin et al, 1999) ; and (6) confirm the safety of a DCvaccination (Roskrow et al, 1999; Ludewig et al, 2000) .
In the present research, we examined the usefulness of Lipofectin™, a commercially available cationic liposome for introducing plasmid DNA, for the introduction of exogenous antigens into DCs by evaluating antigen presentation on MHC class I molecules. In order to identify the DC-immunization protocol that exhibits the most superior anti-tumour effect, we investigated the vaccine efficiency of DC2.4 cells, a murine dendritic cell line, pulsed with ovalbumin (OVA) after i.v., i.p., i.d., or s.c. immunization in the murine E.G7-OVA tumour model. In addition, we investigated the effect of OVA-pulsed DC2.4 cellsimmunization route on the induction of OVA-specific CTL response and on the migration of DC2.4 cells to regional lymph nodes. (Shen et al, 1997) , were grown in complete RPMI 1640 medium (10% fetal bovine serum, 2 mM Lglutamine, 100 µg/ml streptomycin, and 100 U/ml penicillin) supplemented with non-essential amino acid (100 µM) and 2-mercaptoethanol (2-ME: 50 µM). RF33.70 cells (Rock et al, 1990; Shen et al, 1997) were maintained in complete RPMI 1640 medium supplemented with 50 µM 2-ME. CTLL-2 cells, which proliferate specifically in response to interleukin-2 (IL-2) (Harding, 1994) , were maintained in complete RPMI 1640 medium supplemented with 50 µM 2-ME and 10 U/ml murine recombinant IL-2 (Pepro Tech EC LTD., London, England). E.G7-OVA tumour cells (H-2 b ; OVA-transfectant of EL4 murine thymoma cells) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 50 µM 2-ME and 400 µg/ml G418. EL4 cells and YAC-1 cells, which are highly sensitive to natural killer cells (Cikes et al, 1973) , were maintained in complete RPMI 1640 medium supplemented with 50 µM 2-ME.
Female C57BL/6 mice, aged 7-8 weeks, were purchased from SLC Inc. (Hamamatsu, Japan) and held under specified pathogenfree conditions. All of the experimental procedures carried out were in accordance with the Kyoto Pharmaceutical University guidelines on animal experiments and the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia.
Antigen presentation assay
DC2.4 cells were seeded in a 96-well flat-bottom culture plate at a density of 1 × 10 4 cells/well and cultured overnight. Lipofectin™ (Life Technologies, Tokyo, Japan), composed of N-[1-(2,3-dioleyloxy)propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dioleoyl phosphatidylethanol amine (DOPE), was mixed at a final concentration of 10 µg/ml with various concentrations of OVA (Sigma Chemical Co., St Louis, MO, USA) in Opti-MEM (Life Technologies), and incubated for 20 min at room temperature. Each well was washed twice with Opti-MEM, and then the cells were incubated with various concentrations of soluble OVA or OVA-Lipofectin complex in 100 µl of Opti-MEM. After 5-h incubation at 37˚C, each well was washed twice and incubated in the absence or presence of mitomycin C (MMC: 50 µg/ml in Opti-MEM) at 37˚C for 30 min. After washing with Opti-MEM, OVA-pulsed DC2.4 cells were co-cultured with specific T-T hybridoma against OVA + H-2K b , RF33.70 cells (Rock et al, 1990; Shen et al, 1997) . The response of stimulated RF33.70 cells (1 × 10 5 cells/well) was assessed by determining IL-2 released into an aliquot of complete RPMI 1640 medium (200 µl) at 37˚C. Briefly, the culture medium was collected after 20-h co-culturing of OVA-pulsed DC2.4 cells and RF33.70 cells. Serially diluted culture medium was added to the CTLL-2 cells seeded on 96-well flatbottom culture plates at a density of 5 × 10 3 cells/well. Two days later, the number of viable CTLL-2 cells was evaluated by MTT assay (Mosmann, 1983) . The concentration of IL-2 released from RF33.70 cells was calculated from a standard curve obtained from the MTT activity of CTLL-2 cells cultured in the presence of various concentrations of murine recombinant IL-2.
Loading OVA into DC2.4 cells using lipofectin
Lipofectin was mixed at a final concentration of 10 µg/ml with OVA at a final concentration of 1 mg/ml in Opti-MEM, and incubated for 20 min at room temperature. The OVA-Lipofectin mixture was added to a DC2.4 cell pellet (1 × 10 6 cells/ml) that was previously washed twice in Opti-MEM, and the final solution incubated at 37˚C in a water bath with occasional agitation for 5 h. After washing with phosphate-buffered saline (PBS), the cells were treated with MMC (50 µg/ml in Opti-MEM) at 37˚C for 30 min in order to inhibit proliferation. OVA-pulsed DC2.4 cells were then washed twice and resuspended with PBS prior to immunization.
Tumour rejection assay
C57BL/6 mice were immunized once or twice over a 1-week interval with OVA-pulsed DC2.4 cells. Cells (1 × 10 6 cells/100 µl/mouse) were injected into the lateral tail vein (i.v.), peritoneum (i.p.), or right flank (i.d. or s.c.). One week after the final vaccination, 1 × 10 6 E.G7-OVA tumour cells were inoculated into the left flank. Tumour size was assessed three times a week using microcalipers and was expressed as tumour volume, calculated by the following formula (Janik et al, 1975) : tumour volume (mm 3 ) = (major axis) × (minor axis) 2 × 0.5236. Mice with tumour sizes > 2.5 cm or tumour volume > 2500 mm 3 were euthanized. On day 60 after tumour challenge, all survivors were euthanized.
Europium-release assay for detecting OVA-specific CTLs
C57BL/6 mice were immunized once with OVA-pulsed or nonpulsed DC2.4 cells (1 × 10 6 cells). At one week after immunization, spleens were excised and single cells suspensions were prepared. The splenocytes were re-stimulated in vitro with E.G7-OVA cells pre-treated with MMC (50 µg/ml in Opti-MEM) at 37˚C for 30 min, at an effector:stimulator ratio of 10:1 in complete RPMI 1640 medium. Five days after re-stimulation, europium (Eu)-labeling of target cells (E.G7-OVA cells, EL4 cells, and YAC-1 cells) and Eu-release assay were performed according to the methods of Volgmann et al (1989) . In brief, target cells (5-10 × 10 6 ) were labeled with Eu chelate (Eu-diethylenetriamine pentaacetate) for 20 min at 4˚C. Eu-labeled targets (1 × 10 4 cells) were incubated with serially diluted effector cells at various effector:target (E:T) ratios in 100 µl of complete RPMI 1640 medium on 96-well U-bottomed culture plates. The plates were centrifuged at 500 × g for 3 min and incubated at 37˚C for 4 h. The addition of 150 µl of an enhancement solution (Amersham Pharmacia Biotech, Tokyo, Japan) containing β-naphthoyltrifluoroacetone to 50 µl of culture supernatant aliquots leads to the formation of a highly fluorescent Eu-chelate that can be measured with a time-resolved fluorometer (Ex: 340 nm, Em: 612 nm; SPECTARAFLUOR Plus, TECAN, Tokyo, Japan). Specific cytotoxic activity was determined using the following formula: specific lysis (%) = [(experimental Eu-release -spontaneous Eurelease) / (maximum Eu-release -spontaneous Eu-release)] × 100. Spontaneous Eu-release of the target cells was < 10% of maximum Eu-release by detergent in all assays. SEM was less than 5% of triplicate cultures.
Estimation of DC2.4 cells migration to the lymphoid tissues by polymerase chain reaction (PCR)
C57BL/6 mice were injected with 1 × 10 7 OVA-pulsed DC2.4 cells via various routes including i.v. (lateral tail vein), i.p., i.d. (right flank), and s.c. (right flank). At 48 h after injection, mice were sacrificed and thymus, spleen, Peyer's patches and lymph nodes (cervical, brachial, axillary, mesenterial, renal, lumbal, pygal, inguinal, and ischial) were excised and genomic DNA was isolated from these tissues. Because v-myc is inserted in genomic DNA of DC2.4 cells (Shen et al, 1997) , we attempted to estimate the migration of DC2.4 cells to the lymphoid tissues by amplification of the v-myc gene using PCR. The primers for v-myc amplification were designed based on GeneBank data for v-myc derived from avian myelocytomatosis virus (accession No. V01173) and had the following sequence: forward, 5′-AACGAGTCTGAATCCAGC AC-3′; reverse, 5′-TGCAAGACAGAGAGGTTAGC-3′. Genomic DNA isolated from DC2.4 cells was used as a positive control. The amplification conditions were as follows: after denaturation at 94˚C for 2 min, denaturation at 94˚C for 45 s, annealing at 52˚C for 45 s, and extension at 72˚C for 45 s were repeated for 35 cycles and followed by completion at 72˚C for 4 min. The size of the expected PCR product was 414 bp. The PCR product was separated on 3% agarose gel, stained with ethidium bromide, and visualized under ultraviolet radiation. EZ Load™ (BIO-RAD, Tokyo, Japan) was used as a molecular ruler.
RESULTS

DC2.4 cells pulsed with OVA-Lipofectin efficiently present OVA-peptides on MHC class I molecules
In the present study, we used DC2.4 cells, a murine dendritic cell line (Shen et al, 1997) , as APCs. Immunofluorescence analysis and flow cytometry confirmed the expression of MHC class I and II molecules and costimulatory molecules such as B7-1 (CD80), B7-2 (CD86), and CD40 on the surface of DC2.4 cells (data not shown). To investigate antigen presentation of OVA-pulsed DC2.4 cells via MHC class I molecules, we performed an antigen presentation assay by measuring the production of IL-2 from RF33.70 cells specific for OVA peptides bound to MHC class I molecules (Rock et al, 1990; Shen et al, 1997) (Figure 1) . No significant change in IL-2 levels was observed in the co-cultures of soluble OVA-pulsed DC2.4 cells and RF33.70 cells, even when 10 mg/ml of soluble OVA was pulsed onto DC2.4 cells. On the other hand, when pulsed with OVA-Lipofectin (10 µg/ml), DC2.4 cells efficiently presented OVA-peptides on MHC class I molecules in an OVA concentration-dependent manner.
Because DC2.4 cells are an established cell line, the permanent proliferation of DC2.4 cells must be inhibited for in vivo vaccination. Therefore, we examined the effect of 50 µg/ml of MMC on the MHC class I presentation of DC2.4 cells pulsed with OVALipofectin complexes. MMC-treatment did not affect the presentation of OVA-peptides via MHC class I molecules on DC2.4 cells (Figure 1 ). In addition, we confirmed that the MMC-treated DC2. effect of OVA-pulsed DC2.4 cells was OVA-specific because after inoculation with EL4 tumour cells, parent cells of E.G7-OVA tumour growth was not affected by vaccination with OVA-pulsed DC2.4 cells (data not shown). Two vaccinations over a 1-week interval further potentiated the anti-tumour effect of all OVApulsed DC2.4 cell administration routes (Table 1) . Complete protection against E.G7-OVA tumour challenge was achieved in all mice immunized twice with 1 × 10 6 OVA-pulsed DC2.4 cells via i.p., i.d., or s.c. route. Repeating the i.v. immunization failed to achieve complete rejection, although two of four mice were tumour-free on day 21 post-tumour challenge. These results demonstrated that the vaccine efficiency of DCs pulsed with antigens was obviously influenced by the administration route and the immunization schedule. Influence of administration route of OVA-pulsed DC2.4 cells on vaccine efficiency against E.G7-OVA tumour growth. C57BL/6 mice were immunized once via various routes by 1 × 10 6 DC2.4 cells pulsed with OVA (1 mg/ml)-Lipofectin. One week later, 1 × 10 6 E.G7-OVA tumour cells (OVA-transfectant of EL4 mouse thymoma cells) were intradermally inoculated into the left flank. The size of growing E.G7-OVA tumours was measured every 2-3 days using microcalipers. Each group consisted of four mice. †: Two mice were euthanized because tumour volumes were in excess of 2500 mm
Administration routes of OVA-pulsed DC2.4 cells affect OVA-specific CTL response
Antigen-pulsed DC vaccines have been reported to trigger a specific CTL response directly (Paglia et al, 1996; Alters et al, 1998; Wong et al, 1998) . We therefore used the Eu-release assay to determine the influence of OVA-pulsed DC2.4 cell administration route on the induction of the OVA-specific CTL response. Spleen cells were prepared from mice on day 7 after vaccination with OVA-pulsed DC2.4 cells via various routes. Cytotoxic effectors were generated by coculturing spleen cells for 5 days with E.G7-OVA cells treated with MMC. As shown in Figure 3 , strong lytic activity against E.G7-OVA cells was elicited in cultured spleen cells from mice administered OVA-pulsed DC2.4 cells i.d. or s.c. In contrast, moderate and low killing of E.G7-OVA cells was observed in the i.p.-and i.v.-immunized groups, respectively. Cytotoxic activity against EL4 cells and YAC-1 cells, which are highly sensitive to natural killer cells (Cikes et al, 1973) , failed to be generated by vaccination with OVA-pulsed DC2.4 cells. This observation strongly suggested that the lysis of E.G7-OVA cells was due to the OVA-specific CTL activity. Collectively, these results demonstrate that the induction of antigen-specific CTL response is greatly affected by the administration route of the antigen-loaded DCs.
Assessment of OVA-pulsed DC2.4 cell migration to lymphoid tissues
After activation by antigen challenge, DCs mature and migrate to the secondary lymphoid tissues in which they present the processed antigen to naïve T cells (Austyn et al, 1988; Rock, 1996) . Thus, we investigated the migration of OVA-pulsed DC2.4 cells to the lymphoid organs in response to various administration routes. Since the DC2.4 cell line was reported to be established by infection with a retrovirus encoding v-myc and v-raf (Shen et al, 1997) , we determined that the presence of DC2.4 cells in lymphoid tissues after vaccination could be detected by PCR using primer pairs specific for v-myc. Genomic DNA isolated from various lymphoid organs was subjected to PCR and the products were analyzed. In the case of i.d. administration of DC2.4 cells, DNA isolated from lumbal, pygal, inguinal, and ischial lymph nodes produced a PCR product of expected size (414 bp) (Figure 4, third  panel) . In the case of s.c. administration, the specific PCR product was amplified from lumbal, inguinal, and ischial lymph nodes (Figure 4, fourth panel) . In contrast, genomic DNA from various lymphoid tissues failed to generate this PCR product after i.v. and i.p. administration of DC2.4 cells (Figure 4 , first and second panels). These data show that i.d.-and s.c.-administered DC2.4 cells preferentially migrate to the regional lymph nodes, where DC2.4 cells interact with naïve T cells to prime an antigen-specific immune response. Therefore, the differential migration of OVApulsed DC2.4 cells following their administration by the i.v., i.p., i.d., or s.c. routes is reflected in their potency to induce OVAspecific CTL responses.
DISCUSSION
DCs are professional APCs capable of capturing antigens and processing and presenting antigenic peptide fragments. Mature DCs can migrate to lymphoid organs to prime T cell immune responses (Austyn et al, 1988; Rock, 1996; Banchereau and Steinman, 1998) . Due to these properties, DCs are considered promising tools for cancer immunotherapy. For successful DCbased immunotherapies, antigens must be efficiently introduced into DCs and presented on MHC class I molecules at high levels, to activate CD8 + CTLs. We have been exploring methods for loading exogenous antigens into APCs showing high MHC class I presentation efficiency (Hayashi et al, 1999; Nakanishi et al, 2000) . In the present study, we tested the cationic liposome, Lipofectin, for loading an exogenous antigen, OVA, into the murine DC2.4 cell line, which has been reported to possess morphological and functional properties of DCs (Shen et al, 1997) . DC2.4 cells pulsed with OVA-Lipofectin complexes showed more efficient presentation of OVA-peptides on MHC class I molecules than soluble OVA-pulsed DC2.4 cells (Figure 1) . In most cells, antigens in the extracellular fluids do not ordinarily access the MHC class I pathway for antigen presentation. In contrast, DCs have been reported to transfer the exogenous antigens from the endocytic compartment into the cytosol, where they are degraded and presented via the classical MHC class I pathway. This process is markedly enhanced when the antigens are internalized by phago- Spontaneous release in the absence of effector cells was <10% of maximum release by detergent. All data points represent the average of two independent experiments, which were performed with 3-5 mice per group cytosis (Shen et al, 1997) , macropinocytosis (Norbury et al, 1997) , or receptor-mediated endocytosis (Rodriguez et al, 1999; Machy et al, 2000) . In some cases, peptides derived from the exogenous antigens appear to be generated in the endocytic compartments and then bind to MHC class I molecules on the cell surface (Zitvogel et al, 1998) . Although the pathway of internalized OVALipofectin complexes in DC2.4 cells remains to be elucidated, we speculate that the transfer of OVA to the MHC class I pathway may be greatly facilitated by Lipofectin because DC2.4 cells used phagocytosis not pinocytosis to capture exogenous OVA associated with Lipofectin. Elucidation of intracellular trafficking of antigens loaded with Lipofectin and of the transport mechanism of the antigen-Lipofectin complex in DCs is important for establishing methods for efficient introduction of antigens into DCs showing high MHC class I presentation efficiency.
Several studies have shown that ex vivo-differentiated DCs may enable specific vaccination for generating protective tumour immunity in human clinical trials (Hsu et al, 1996; Nestle et al, 1998; Lodge et al, 2000) . However, it is still unclear which DC administration route elicits superior therapeutic effects in DC-based immunotherapy. In order to elucidate this issue, we performed E.G7-OVA tumour rejection assays in mice immunized via various administration routes with DC2.4 cells pulsed with OVALipofectin complexes. Although tumour growth was delayed in all groups, the ratio of complete rejection on day 60 after tumour challenge differed with the administration route of OVA-pulsed DC2.4 cells (Table 1) . Moreover, the anti-tumour effect was enhanced in all groups by a twice repeated vaccination with OVApulsed DC2.4 cells. These results suggest that the route of administration and the immunization schedule of OVA-pulsed DC2.4 cells affect the induction of OVA-specific host immunity. In addition, these results are confirmed by the OVA-specific CTL response after vaccination with OVA-pulsed DC2.4 cells via various routes. High cytotoxicity due to OVA-specific CTLs was shown in splenocytes isolated from mice injected i.d. and s.c. with OVA-pulsed DC2.4 cells, whereas moderate and low CTL response was observed in i.p. and i.v. administered mice, respectively (Figure 3) . The magnitude of OVA-specific CTL response induced by immunizing with OVA-pulsed DC2.4 cells, positively correlated with the results of the E.G7-OVA tumour rejection assay for each vaccination route.
The migration of antigen-loaded DCs to secondary lymphoid tissues is essential for efficient induction of the antigen-specific CTL response. Lappin et al (1999) reported that DCs were found in popliteal lymph nodes at 24 h following their s.c. injection into footpads. The number of DCs peaked at 48 h and decreased to background levels by day 5 after injection (Lappin et al, 1999) . Based on their report, we investigated by PCR the migration of OVA-pulsed DC2.4 cells to the lymphoid tissues, 48 h after injection. The PCR product for v-myc was successfully amplified from genomic DNA isolated from the regional lymph nodes of i.d.-or s.c.-injected mice, while no PCR products were found in any lymphoid tissues of i.v.-or i.p.-injected mice (Figure 4) . These results clearly indicate that the DC2.4 cells administered i.d. or s.c. preferentially migrated to the regional lymph nodes as compared with i.v.-and i.p.-injected DC2.4 cells. Therefore, we reasoned that the various anti-E.G7-OVA tumour effects of OVA-pulsed DC2.4 cells reflected the extent of their migration to the regional lymph nodes and thereby the induction of OVA-specific CTL response.
Recent advances in biological and immunological research on DCs have introduced the potential use of specific antigen-loaded DCs as nature's adjuvant against cancer. DC-based immunotherapy is expected to show strong anti-tumour effects against microscopic metastases that are otherwise incurable. However, further studies are required to improve the effectiveness of DCbased immunotherapy. In the present report, we provided evidence that the administration route affected the migration of antigenloaded DCs to the regional lymph nodes and thereby dominated host tumour immunity based on the antigen-specific CTL response. These results demonstrate that the route of administration of DCs should be considered as an important variable when designing vaccination protocols using DCs loaded with antigens. N 1 2 3 4 5 6 7 8 9 10 11 12 P M N 1 2 3 4 5 6 7 8 9 10 11 12 P M N 1 2 3 4 5 6 7 8 9 10 11 12 P M N 1 2 3 4 5 6 7 8 9 10 11 12 P M Figure 4 PCR analysis of the migration to the lymphoid tissues of DC2.4 cells pulsed with OVA. C57BL /6 mice were injected via various routes with 1 × 10 7 OVA-pulsed DC2.4 cells. After 48 h, lymphoid tissues were removed and genomic DNA was isolated. PCR was performed using a primer pair specific for v-myc. Lane N is negative control run in parallel in the absence of DNA. Lanes 1-12 represent cervical lymph nodes, brachial lymph nodes, axillary lymph nodes, thymus, mesenterial lymph nodes, Peyer's patches, renal lymph nodes, lumbal lymph nodes, pygal lymph nodes, inguinal lymph nodes, ischial lymph nodes, and spleen, respectively. Lane P is a positive control using DC2.4 cells-derived genomic DNA. Lane M is a 100 bp-molecular ruler
